TP53 mutations and protein immunopositivity may predict for poor outcome but also for trastuzumab benefit in patients with early breast cancer treated in the adjuvant setting.

doi:10.18632/oncotarget.9022

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

TP53 mutations and protein immunopositivity may predict for poor outcome but also for trastuzumab benefit in patients with early breast cancer treated in the adjuvant setting.

Oncotarget - 31 May 2016

Fountzilas George, Giannoulatou Eleni, Alexopoulou Zoi, Zagouri Flora, Timotheadou Eleni, Papadopoulou Kyriaki, Lakis Sotiris, Bobos Mattheos, Poulios Christos, Sotiropoulou Maria, Lyberopoulou Aggeliki, Gogas Helen, Pentheroudakis George, Pectasides Dimitrios, Koutras Angelos, Christodoulou Christos, Papandreou Christos, Samantas Epaminontas, Papakostas Pavlos, Kosmidis Paris, Bafaloukos Dimitrios, Karanikiotis Charisios, Dimopoulos Meletios-Athanassios, Kotoula Vassiliki

Abstract excerpt

BACKGROUND: We investigated the impact of PIK3CA and TP53 mutations and p53 protein status on the outcome of patients who had been treated with adjuvant anthracycline-taxane chemotherapy within clinical trials in the pre- and post-trastuzumab era. RESULTS: TP53 and PIK3CA mutations were found in 380 (21.5%) and 458 (25.9%) cases, respectively, including 104 (5.9%) co-mutated tumors; p53 immunopositivity was...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents, Immunological

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Chemotherapy, Adjuvant

Share to Class I Phosphatidylinositol 3-Kinases

Share to Clinical Trials as Topic

Share to Greece

Share to Patient Selection

Share to Trastuzumab

Share to Triple Negative Breast Neoplasms

Source

Open in PubMed Open full text

Identifiers

PMID: 27129168
DOI: 10.18632/oncotarget.9022
PMCID: PMC5078047

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

TP53 mutations and protein immunopositivity may predict for poor outcome but also for trastuzumab benefit in patients with early breast cancer treated in the adjuvant setting.PMID 27129168Read ↗

Effects of TP53 and PIK3CA mutations in early breast cancer: a matter of co-mutation and tumor-infiltrating lymphocytes.Semantic proximity Read ↗

Somatic mutation profiling and associations with prognosis and trastuzumab benefit in early breast cancer.Semantic proximity Read ↗

Role of TP53 mutations in triple negative and HER2-positive breast cancer treated with neoadjuvant anthracycline/taxane-based chemotherapy.Semantic proximity Read ↗

Real-world Comparison of P53 Immunohistochemistry and TP53 Mutation Analysis Using Next-generation Sequencing.Semantic proximity Read ↗

TP53 status for prediction of sensitivity to taxane versus non-taxane neoadjuvant chemotherapy in breast cancer (EORTC 10994/BIG 1-00): a randomised phase 3 trial.Semantic proximity Read ↗

Aberrant p53 immunostaining patterns in breast carcinoma of no special type strongly correlate with presence and type of TP53 mutations.Semantic proximity Read ↗

P53 immunohistochemistry is an ideal surrogate marker for TP53 mutation and a predictor of early metastasis in breast cancer: Real-world analysisSemantic proximity Read ↗

Anthracycline-Free Neoadjuvant Treatment in Patients with HER2-Positive Breast Cancer: Real-Life Use of Pertuzumab, Trastuzumab and Taxanes Association with an Exploratory Analysis of PIK3CA Mutational StatusSemantic proximity Read ↗

Outcome impact of PIK3CA mutations in HER2-positive breast cancer patients treated with trastuzumab.Semantic proximity Read ↗

Molecular landscape of TP53 mutations in breast cancer and their utility for predicting the response to HER-targeted therapy in HER2 amplification-positive and HER2 mutation-positive amplification-negative patients.Semantic proximity Read ↗

Predictive and prognostic role of p53 according to tumor phenotype in breast cancer patients treated with preoperative chemotherapy: a single-institution analysis.Semantic proximity Read ↗

Prognostic and predictive value of TP53mutations in node-positive breast cancer patients treated with anthracycline- or anthracycline/taxane-based adjuvant therapy: results from the BIG 02-98 phase III trialSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.